- Home
- BKYI vs ONCO Comparison
BKYI vs ONCO Comparison
Compare BKYI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- ONCO
- Stock Information
- Founded
- BKYI 1993
- ONCO 2018
- Country
- BKYI United States
- ONCO United States
- Employees
- BKYI N/A
- ONCO N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- ONCO Health Care
- Exchange
- BKYI Nasdaq
- ONCO Nasdaq
- Market Cap
- BKYI 5.3M
- ONCO 4.7M
- IPO Year
- BKYI 1997
- ONCO 2022
- Fundamental
- Price
- BKYI $0.85
- ONCO $3.58
- Analyst Decision
- BKYI
- ONCO
- Analyst Count
- BKYI 0
- ONCO 0
- Target Price
- BKYI N/A
- ONCO N/A
- AVG Volume (30 Days)
- BKYI 13.8M
- ONCO 65.4K
- Earning Date
- BKYI 11-13-2025
- ONCO 12-09-2025
- Dividend Yield
- BKYI N/A
- ONCO N/A
- EPS Growth
- BKYI N/A
- ONCO N/A
- EPS
- BKYI N/A
- ONCO N/A
- Revenue
- BKYI $6,911,148.00
- ONCO $1,326,959.00
- Revenue This Year
- BKYI $7.45
- ONCO N/A
- Revenue Next Year
- BKYI $23.29
- ONCO N/A
- P/E Ratio
- BKYI N/A
- ONCO N/A
- Revenue Growth
- BKYI N/A
- ONCO N/A
- 52 Week Low
- BKYI $0.62
- ONCO $2.45
- 52 Week High
- BKYI $3.68
- ONCO $305.15
- Technical
- Relative Strength Index (RSI)
- BKYI 53.90
- ONCO 55.84
- Support Level
- BKYI $0.73
- ONCO $3.48
- Resistance Level
- BKYI $1.97
- ONCO $3.65
- Average True Range (ATR)
- BKYI 0.13
- ONCO 0.21
- MACD
- BKYI 0.02
- ONCO -0.01
- Stochastic Oscillator
- BKYI 11.01
- ONCO 39.18
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.